# Study of Bevacizumab Alone or Combined With Capecitabine and Oxaliplatin as Support Therapy in Metastatic Colorectal Cancer Patients

> **NCT00335595** · PHASE3 · COMPLETED · sponsor: **Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)** · enrollment: 480 (actual)

## Conditions studied

- Colorectal Cancer

## Interventions

- **DRUG:** XELOXA
- **DRUG:** XELOXA-A

## Key facts

- **NCT ID:** NCT00335595
- **Lead sponsor:** Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-07
- **Primary completion:** 2012-06
- **Final completion:** 2012-06
- **Target enrollment:** 480 (ACTUAL)
- **Last updated:** 2013-02-20

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00335595

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00335595, "Study of Bevacizumab Alone or Combined With Capecitabine and Oxaliplatin as Support Therapy in Metastatic Colorectal Cancer Patients". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT00335595. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*